Share-based Payment Arrangement, Expense in USD of Elevation Oncology, Inc. from Q2 2020 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Elevation Oncology, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q2 2020 to Q1 2025.
  • Elevation Oncology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $987,000, a 9.4% increase year-over-year.
  • Elevation Oncology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $4,365,000, a 57% increase year-over-year.
  • Elevation Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,280,000, a 28% increase from 2023.
  • Elevation Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,335,000, a 4% increase from 2022.
  • Elevation Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,206,000, a 104% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Elevation Oncology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $4,365,000 $987,000 +$85,000 +9.4% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $4,280,000 $1,177,000 +$893,000 +314% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $3,387,000 $1,154,000 +$311,000 +37% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 $3,076,000 $1,047,000 +$303,000 +41% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $2,773,000 $902,000 -$562,000 -38% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $3,335,000 $284,000 -$575,000 -67% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $3,910,000 $843,000 -$40,000 -4.5% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $3,950,000 $744,000 -$93,000 -11% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $4,043,000 $1,464,000 +$837,000 +133% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $3,206,000 $859,000 +$170,000 +25% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 $3,036,000 $883,000 +$224,000 +34% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $2,812,000 $837,000 +$679,000 +430% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $2,133,000 $627,000 +$562,000 +865% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $1,571,000 $689,000 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $659,000 +$644,000 +4293% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $158,000 +$146,000 +1217% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $65,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 $15,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $12,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2

Elevation Oncology, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,280,000 +$945,000 +28% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $3,335,000 +$129,000 +4% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $3,206,000 +$1,635,000 +104% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
2021 $1,571,000 +$1,519,000 +2921% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $52,000 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.